


Supplemental Information

Dual Targeting of Mesothelin and CD19

with Chimeric Antigen Receptor-Modified

T Cells in Patients with Metastatic Pancreatic Cancer

Andrew H. Ko, Alexander C. Jordan, Evan Tooker, Simon F. Lacey, Renee B. Chang, Yan Li, Alan P. Venook, Margaret Tempero, Lloyd Damon, Lawrence Fong, Mark H. O'Hara, Bruce L. Levine, J. Joseph Melenhorst, Gabriela Plesa, Carl H. June, and Gregory L. Beatty



Supplementary Figure 1. Study Schema. Eligible patients underwent screening and leukopheresis. CAR T cells were manufactured. Patients then received a single dose of cyclophosphamide (1.5 g/m²) on day -4 prior to receiving a 1:1 mixture of CART-Meso (3x10⁷ cells/m²) and CART-19 (3x10⁷ cells/m²) cells administered on day 0. Patients were followed for safety and blood samples were collected at defined timepoints prior to and post CART cell administration.

Supplementary Table 1. CART-meso cell product characteristics

Patient	CD45⁺ CD3⁺	CD3⁺ CD4⁺	CD45⁺ CD3⁺ CD4⁺	%CD3⁺ CD8⁺	CD45⁺ CD3⁺ CD8⁺	CD4:CD8 ratio	% scFV	Viability
19214-01	95.80%	81.70%	78.30%	23.30%	22.30%	3.51	27.60%	95.80%
19214-03	97.20%	67.90%	66.00%	35.60%	34.60%	1.91	34.10%	97.60%
19214-04	98.00%	69.40%	68.00%	34.00%	33.30%	2.04	49.40%	100.00%

Supplementary Table 2. CART-19 cell product characteristics

Patient	CD45⁺ CD3⁺	CD3⁺ CD4⁺	CD45⁺ CD3⁺ CD4⁺	%CD3⁺ CD8⁺	CD45⁺ CD3⁺ CD8⁺	CD4:CD8 ratio	% scFV	Viability
19214-01	98.00%	80.90%	79.30%	21.60%	21.20%	3.74	5.57%	99.00%
19214-03	98.40%	66.70%	65.60%	35.80%	35.20%	1.86	29.20%	97.10%
19214-04	98.60%	71.60%	70.60%	30.10%	29.70%	2.38	31.80%	100.00%

Supplementary Table 3. Human anti-mouse antibody quantification in patient sera

Subject	Pre-infusion	Day 21-28	Month 2
19214-01	nd	nd	nd
19214-03	26.5	9.66	6.05
19214-04	nd	nd	na

HAMA=ng/mL; na, not assessed; nd, not detected